NCT02704390 - Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

ORADUR®-Methylphenidate

ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.

Trial Locations (3)

100

National Taiwan University Hospital, Taipei

Unknown

Chang Gung Medical Foundation- Chiayi Branch, Chiayi City

Chang Gung Medical Foundation- Linkuo Branch, Taoyuan District